11 min read5 viewsinvesting

Medsider: Do the Hard Thing First, and You Earn the Right to Do More

Early morning in a clean room, a shallow tray of a few dozen clear patches on a stainless steel bench in the foreground beside a pulled-off glove and a closed notebook, the room receding behind into racking and the cold reflection of a row of fluorescent tubes

Notes on the Medsider episode of 9 November 2026, where Scott Nelson talks with Marcus Mounir Hanana, CEO of Panther Life Sciences. He spent about 25 years between P&G and Amazon, the last four as CFO of Amazon Business, which grew from roughly $25bn to $60bn under his watch; in 2026 he took over a company of fewer than twenty people making dissolving microneedle patches. At the time of recording they were hand-making 100 to 150 patches a day in a clean room, up from five to ten a day a month earlier, with the first product planned for summer 2027. Every figure is as he stated it on the show. Educational listening notes only — no investment advice, no price targets, and my reading may be wrong.

  • medtech
  • podcast-notes
  • manufacturing ramp
  • startup operating
  • execution
Contents
  1. Asked about his career, the thing he picks out is an empty field
  2. One remark from his wife sent him to a summer programme at Stanford
  3. Five a day a month ago, 150 a day now
  4. A company of under twenty people, where three words on a slide is not an answer
  5. When a company says it is “ready to scale production,” how do I judge that sentence?
  6. Why I get my highest-conviction holding wrong most often
  7. Worth a look
  8. The one thing to take with you

Early morning in a clean room, a shallow tray of a few dozen clear patches on a stainless steel bench in the foreground beside a pulled-off glove and a closed notebook, the room receding behind into racking and the cold reflection of a row of fluorescent tubes

The spirit helps me! All at once I see my way and write with confidence: in the beginning was the deed.

—— Goethe, “Faust”, Part One, the study scene (1808; my own translation)

In the Medsider episode of 9 November 2026, host Scott Nelson talks with Marcus Mounir Hanana, CEO of Panther Life Sciences — he took the seat in 2026 at a company of fewer than twenty people whose product is a microneedle patch that dissolves into the skin. Mounir spent about 25 years between P&G and Amazon, the last four as CFO of Amazon Business, a business that went from roughly $25bn to $60bn while he held the role. On the show he says they were hand-making five to ten patches a day a month before the recording and 100 to 150 a day in a clean room at the time of it, with a first product planned for the summer of 2027. His own test is this: do the hard thing first and you earn the right to do more — and the condition attached is that the company has to pick a simple market with no drug-approval gate and walk the entire supply chain end to end once.

Asked about his career, the thing he picks out is an empty field

P&G had a large plant in France and needed another for all of Eastern Europe, so they found a site in the eastern part of Romania, in the middle of nowhere. He says there was nothing there when he arrived; two years later a line was running, there was a factory, people worked in it, and product came out. He calls it one of the most fulfilling things he has done, and the reason is plain: a physical product is tangible.

Amazon was a continuation of the same thing, because he was still dealing with physical goods. A digital product can be written once and distributed instantly; the moment you have to produce something or move something, the physical world is there, and the physical world is sometimes against you — there is weather, and there are a lot of people to take care of. So the line he carried out of P&G is that the idea is often quicker than the execution. You have the idea today, and then you need manufacturing, a supply chain, a brand, communication, all of it detailed work, and that detailed work is the outcome.

One remark from his wife sent him to a summer programme at Stanford

He studied mathematics, always wanted to do an MBA, and never did. Two years ago he raised it with his wife, who said: doesn’t it start being a little weird now, still doing one? You’re getting old. So instead of the MBA he went to Stanford for a summer programme, and came back wanting a smaller company more than before.

What actually moved him was what Panther is building. The figures he cites on the show: about two billion people in the world are untreated and about 4.6 billion undertreated, largely because of how treatments are delivered — a syringe or a pill; the US pharma industry loses around $35bn a year to cold chains breaking down; and about half of all vaccines globally get thrown away. Panther’s product is a patch whose needles are made of formula, so you put it on your skin and they dissolve, and the thing is shelf-stable. The picture in his head, he says, was putting one in a letter envelope and sending it anywhere in the world.

Two panels of twenty squares each: on the left, half of the squares are crossed out and left empty, while on the right all twenty squares are completely filled.

The skin section is the hardest reasoning in the episode, and the figures below are all as he gave them. Your skin’s whole job is to keep things out, and nothing above about 500 daltons (the unit of molecular weight) gets through, while collagen is a protein at 5,000 to 10,000 daltons. So the collagen printed on the jar is not getting into your skin; only around 1% of a topical passes, and the rest washes off. Past that first layer, the stratum corneum, is where it gets interesting: skin has immune-activation properties the rest of the body does not have, and Jenner cutting cowpox into a boy’s arm in 1796 was already using it. Mounir is blunt about where the company sits: they are commercialising skin biology that is already known, and a Nobel Prize is not the goal.

A wall with a narrow gap lets small dots pass through, while a much larger circle is blocked and bounces back, and the thin bar below is filled only at its left end.

His other two reasons for joining are worth logging: the founder, Carlos, is a serial entrepreneur he wanted to learn from, and the company already holds over a hundred pieces of intellectual property while being ready to commercialise, with no intention of staying scientific for another decade.

Five a day a month ago, 150 a day now

This is the part I most wanted to write down. He says it is easy to sit and discuss what the product should look like, make nice graphs, have a couple of scientists work out the next molecule, and everyone is happy; it is when you start producing ten a day, a hundred a day, a thousand a day that you discover this is hard. So their approach is to do the hard part first and earn the right to do more. His own challenge to it is sharper: what does it help me to work out how to encapsulate a molecule in a vaccine ten years from now if I have never made more than twenty or a hundred of these? I would still have no solution.

In practice that is the three numbers. A month before: five to ten a day, by hand. At the time of recording: 100 to 150 a day in a clean room, still manual, but enough to run one clinical trial and then another. Next comes a first manual line, drawn up with engineering partners, and once the manual line exists they can work on automating it. His image for it is that you crawl before you walk.

Three bars rise from short to tall, from five units a day to a hundred and fifty, up to a dashed target bar at one million, and the height gaps show three different orders of magnitude at a glance.

The reason the first product is a cosmetic runs along the same line. His account is that the category has no drug-approval gate, so they can walk the full value chain once and watch real people use the thing and feel how it feels — for a new product format there is no substitute for seeing that. At the same time he draws the quality line hard: the ingredients have to be the best grade obtainable, so if there is hyaluronic acid in it, it comes from the best producer on the planet; this is a premium line, not a $3.99 discount product. He says that line makes decisions simpler in reverse: once you are clear about what you are building, the decision is already made for you, and an option that violates the first tenet simply stops being an option — which puts the bar for violating it very high. Inside the patch there is also a chip. Your phone goes near it, the app opens, scans your face, tells you where to place the patch, takes before and after pictures, reads whether it worked and sets the interval for the next one. Today, he points out, you see a doctor and get told to apply a cream twice a day, when you might need it once or three times — the problem is that nobody knows. At the time of recording they had completed early human safety and tolerability studies and had a 40-person efficacy study running.

A company of under twenty people, where three words on a slide is not an answer

He brought two things with him. The first is that the consumer is the boss. He recalls A.G. Lafley, P&G’s CEO at the time, repeating it in every meeting until people were sick of hearing it: someone would explain how they wanted to position a brand and sell it, and he would ask what the consumer thinks, what she wants, whether we understand that.

The second is writing. At Amazon you write PR FAQs — a press release for a product that does not exist yet — so you have to answer what you want the user saying about it. How cool the technology is and what features it has buys you nothing there. The documents they took upstairs took about an hour and a half to read and then two and a half hours to discuss, with no room for “that wasn’t clear to me.”

A four-quadrant chart with content depth on the vertical axis and polish on the horizontal axis, where twenty pages and one or two pages both sit in the upper half and three words on a slide sits alone in the lower right corner.

Moving it to Panther, he changed the size: he does not ask his team for twenty pages, one or two will do, but it cannot be three words on a slide. His rule fits in four words — content goes over form. Ugly is fine, unformatted is fine, the content has to be right and the polish can come later. He also warns himself against transplanting: good ideas need adapting when they move, and pushing the original version through stubbornly is the wrong move.

The people part is the other highlight. Inside the company the saying is: when we don’t know what to do, call a friend. What they want is smart money — of the people on their investor list, he says he would spend two weeks on an island with them and not be bored for a minute. Among the advisors is Ken Gabriel, who leads Pitt BioForge and was deputy director of DARPA, and who helped them think about manufacturing early, because from day one the company said this cannot stay an idea and has to reach millions of units. There is also Gordon Sanghera, founder of the London-listed Oxford Nanopore, whom he calls when manufacturing throws up a problem and with whom he has a standing one-on-one. His biggest takeaway, looking back, is that you do not need all the resources on day one: if you can get people excited about your cause, the help you get is more than you would have imagined. Advisors and investors also reinforce each other — investors gain confidence from seeing those advisors show up, and advisors engage more when they see the investors contributing as well.

When a company says it is “ready to scale production,” how do I judge that sentence?

This is where I get stuck most often: a filing or a news story says breakthrough achieved, ready for production, and I cannot tell whether that is progress or something said for an audience.

The episode hands over a ready-made ruler — ask how many a day. Five, 150 and a million are three different companies, and the technology story can be word for word the same. Two layers below that: is it by hand or on a line, and is the line manual or automated? His line about platforms works directly as a test: if you have to keep hiring to grow it, something is wrong. So the ratio of headcount growth to output growth is more useful than addressable market size.

Two small charts side by side plot headcount on the horizontal axis and output on the vertical axis, where the left curve rises almost vertically and the right one is a straight forty-five degree line.

The third layer is the time scale. He keeps two things separate himself: the cosmetic line is planned for next summer, while getting a molecule qualified as a vaccine is, in his words, a ten-year job. Two timelines out of one technology, a generation apart. My own failing is logging “we have the IP” as progress, when there are two layers between intellectual property and making it, and then making it and selling it. Panther holds over a hundred pieces of IP, and what Mounir talks about is how many a day.

Two horizontal bars start from the same point, the top one very short and ending next summer, the bottom one stretching out to ten years.

Why I get my highest-conviction holding wrong most often

This one has bitten me. On products I use myself and industries I know, my judgement comes easiest, and my error rate is highest.

His example made me laugh. He worked on male shaving at P&G; as a man he knows what shaving feels like, so he had an opinion. Then he worked on female hygiene, where he had no intuition at all — and he says that was better, because he listened far more carefully. His conclusion is that humans form an instant opinion about products they can use themselves, and the discipline is this: I might have an intuition, I might have an opinion, but I should act as though I don’t.

Each of the two panels holds one large circle and one small circle: on the left the opinion circle is large and the listening circle small, and on the right it is exactly the other way around.

Translated into something I can do, it is one question: how much of my judgement about this company comes from being its user? Liking a café’s coffee and that café making money are two separate questions. Panther’s answer was to assemble a board of the best dermatologists in the US, because someone who has done it for thirty-plus years knows more about this than he does; my version of that move is to go ask people who are currently paying to use the product, and look less at how smoothly I use it myself.

I try not to push the discipline to its extreme. I keep the intuition, I just write it down as a hypothesis first and go ask three people who are currently paying to use the thing, and decide after that whether to believe it.

Worth a look

  • The Medsider episode of 9 November 2026, the source for this piece, hosted by Scott Nelson
  • Panther Life Sciences’ site, pantherls.com, and the technology and team pages mentioned on the show
  • The University of Pittsburgh’s body of work on dissolving microneedle patches, and the manufacturing collaboration with Pitt BioForge
  • Dermatology literature on stratum corneum penetration, including the rough 500-dalton ceiling
  • The scientific history of Jenner’s 1796 cowpox inoculation, and later work on dendritic cells in skin immunity
  • Public write-ups of Amazon’s internal PR FAQ and long-document practice

The one thing to take with you

The right is earned by making something. Your evidence that you may do the bigger thing is a thing you have already produced.

Every thread in this episode points there. The piece Mounir is proudest of is an empty field in Romania turning into a production line; he will not let the team sit in the science stage, so the first product is the category with the lowest gate; he wants one page whose content is right; he says he does not know how manufacturing will be done, but he knows a group of people who will work the path out. The IP sits there, and what he talks about is 150 a day. The line he would whisper to his younger self says the same thing: keep your focus on the prize, don’t get scared of the how, the path unfolds as you walk.

Here is something I have tried that also works outside investing. Take one thing you have been talking about for a while and have not started — writing something, opening a small shop, turning your parents’ photos into one album, learning an instrument — and this week shrink it to the smallest thing you can actually produce: five hundred words, a trial menu of ten items, a twenty-page album, four bars played all the way through. Then hand the finished thing itself to a real person.

This article is an educational discussion of investment method. It is not advice to buy or sell any individual security, offers no target prices, and does not analyze any current holding. Investing carries risk; make your own decisions or consult a qualified professional.

Comments

Loading comments…

Sign in with Google before posting. Only your name and profile picture are shown.